randomised controlled trial – Page 37 – Communicable Diseases Research

Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 ambulance service assistant Bacillus BCG BCG vaccination BCG-vaccine blinded Care Community Controlled COVID-19 COVID-19 infection COVID-19 pandemic cumulative Denmark dissemination elderly element facilitate HCW HCWs Health care Health care worker Health-care workers hospital Hospital admission hospitals incidence Intervention intervention group investigators Medicine NaCl Netherlands number objective outcome outcome assessor parallel group participant Patient physician Placebo placebo group placebo-controlled protocol randomised randomised controlled trial Randomized randomized trial recruitment reduce Registered registry Research Sample size status stratified Study protocol the placebo group Trial vaccination Vaccine website
[DOI] 10.1186/s13063-020-04389-w PMC 바로가기 [Article Type] Letter

Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 7-point ordinal scale accelerate activities activity acute respiratory syndrome adaptive addition administration Admission airway Akershus allocation sequence Analysis anticipated approach automatically baseline Biochemistry Biomarker blinded Blinding Blood C-reactive protein cardiac troponin Chloroquine clinical Clinical outcome Clinical practice clinical status clinical symptom collected condition coronavirus coronavirus disease COVID-19 Culture database Department disease dissemination early treatment element Endpoint examined excluded extracorporeal membrane oxygenation Good harmonization hepatic injury history hospital Hospital admission hospitalisation hospitalised hospitalised patient Hospitalized Hydroxychloroquine Hypothesis In-hospital include independent Inpatient intensive care intensive care unit International Conference Intervention intervention arm Invasive mechanical ventilation Laboratory marker Microbiology Mortality nasopharyngeal NEWS2 non-invasive ventilation Norway number Nurse objective open label Oropharyngeal Oropharyngeal sampling outcome oxygen participant Patient patients peptide Placebo polymerase chain polymerase chain reaction positive Practice Pragmatic pragmatic trial primary endpoint profile Prolonged Protein protocol QT interval randomisation randomised randomised controlled randomised controlled trial randomization Randomized Randomized controlled trial recruited recruitment Registered renal requiring supplemental oxygen resource responsible RT-PCR Safe Sample size SARS-CoV-2 SARS-CoV-2 viral load score secondary Seven standard care statistical analyses status Study protocol subjects Surveillance therapy transcriptase Treatment treatment allocation Trial Two-arm university use of hydroxychloroquine Viral load virological clearance viruses vital signs website
[DOI] 10.1186/s13063-020-04420-0 PMC 바로가기 [Article Type] Letter

The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hours acid Administered Affect analyst Anti-viral anticipated Beijing block block randomization Blood Body Capital cardiovascular system Care center changed Chinese clinical clinical manifestation Clinical outcome Clinical studies clinical trial college Complete condition Consent control group Corona Corona virus cough COVID-19 criteria curative Diagnosis discharge discharged disease Diseases dissemination dose drug Ebola virus element eligibility criteria enrolled expected experimental group Favipiravir female Follow-up form hepatology history hospital include Including Infection Infectious disease Informed inhibit investigators kidney lack lactating women life-threatening liver Loss male Measures mechanism Medicine Mental Disorders Nasopharyngeal swab nasopharyngeal swabs not blinded nucleic acid nucleic acid test number objective open label oral administration outcome outcome assessors Oxygen therapy parallel group participant Participants Patient plan poor compliance positive protocol Public pulmonary randomised randomised controlled trial randomization system Randomized controlled trial Randomly recruited recruitment reduced Regular Reinfection Research researcher respiratory specimen response returned RNA-dependent RNA polymerase routine screening visit second secondary severe adverse events severity severity of symptoms Shenzhen specimens sputum status Study protocol subject Symptom Symptoms System temperature Test tested therapeutic efficacy throat swabs Traditional Treatment treatment for COVID-19 treatment group Trial uncontrolled university variety viral nucleic acid virus Web website Withdrawal Wuhan
[DOI] 10.1186/s13063-020-04430-y PMC 바로가기 [Article Type] Letter

Umbilical cord blood therapy to prevent progression of COVID-19 related pneumonia: a structured summary of a study protocol for a pilot randomised controlled trial

Letter

Published on 2020-06-042022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 24 hour acute COVID-19 administration Anti-inflammatory ARDS block Blood blood cell Cell cells clinical Clinical improvement control group Cord blood COVID-19 COVID-19 patients dissemination dose Efficacy element Estimated feasibility feasible hospitalised patient immunomodulatory properties infected with SARS-CoV-2 injection intravenous Melbourne, Australia moderate New number objective occur outcome participant Patient Placebo Pneumonia Prevent progression protocol randomised randomised controlled trial RCT recruit recruitment Registered registry Safety Sample size SARS-COV-2 infection sealed severe ARDS severe pneumonia Standard status stem cells Study protocol supportive care therapy Tolerability Total Treatment Trial Umbilical cord umbilical cord blood virus website
[DOI] 10.1186/s13063-020-04387-y PMC 바로가기 [Article Type] Letter